Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Censa Pharmaceuticals
Orphan Technologies |
| gptkbp:CEO |
gptkb:Eric_Dube
|
| gptkbp:focusesOn |
hepatology
nephrology rare diseases |
| gptkbp:formerName |
Retrophin, Inc.
|
| gptkbp:foundedYear |
2011
|
| gptkbp:founder |
gptkb:Martin_Shkreli
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Travere Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:numberOfEmployees |
approximately 350 (2023)
|
| gptkbp:product |
gptkb:Chenodal
gptkb:Cholbam gptkb:Thiola FILSPARI (sparsentan) |
| gptkbp:tradedOn |
NASDAQ: TVTX
|
| gptkbp:website |
https://travere.com
|
| gptkbp:bfsParent |
gptkb:PhRMA
|
| gptkbp:bfsLayer |
6
|